Health Care/Hospital

Medit Launches AuraVue: A Unified 3D Intraoral Scan and X-Ray Visualization Powered by Overjet AI

NEWPORT BEACH, Calif., Dec. 9, 2025 /PRNewswire/ -- Medit, a global leader in 3D intraoral scanning and digital dentistry solutions, today announced the launch of AuraVue, a next-generation visualization and consultation platform that integrates Overjet's AI technology to deliver real-time diagno...

2025-12-09 21:30 965

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into ...

2025-12-09 19:55 1048

AI CAD-OCI Integration Underway: ALL CONEC Begins Validation of Digital Prosthetic Data Workflow

SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ -- ALL CONEC has been chosen as a participant in the Dream Venture Star 11 Oracle × Uclick Program and will begin validating a unified data workflow for digital prosthetic production. The initiative focuses on integrating design, fabrication, and insp...

2025-12-09 19:55 949

Dimora Medical Recognized as Key Driver in Winner Medical's Amazon Award

NEW YORK, Dec. 9, 2025 /PRNewswire/ -- Winner Medical, the parent company of Dimora Medical, has been honored with the Paid Service Operation Excellence Award at the 2025 Amazon Global Selling Seller Conference, which focuses on excellence, innovation and global market. As one of Winner Medical's...

2025-12-09 18:35 780

ISLAND HOSPITAL NAMED MALAYSIA'S FIRST FLAGSHIP MEDICAL TOURISM HOSPITAL

GEORGETOWN, Malaysia, Dec. 9, 2025 /PRNewswire/ -- Island Hospital is the winner ofMalaysia's first Flagship Medical Tourism Hospital (FMTH) programme, a recognition of its consistent standards in care, safety and patient experience for international patients.

2025-12-09 18:18 1452

Seven Zonta Clubs in Hong Kong unite to promote "Zonta Says NO to Violence Against Women" campaign and to support the Po Leung Kuk's mobile art exhibition "Violence? Love!!: A Voyage of Discovery"

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- The recent tragic fire at Tai Po has brought sadness and loss to our community. The seven Zonta Clubs inHong Kong would like to express our deepest condolences to the victims and to extend our sympathy to all those affected. The swift response from all sect...

2025-12-09 18:05 1104

Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025

SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights includ...

2025-12-09 18:00 858

VSure and HEYDOC Health Introduce CareConnect Suite, Transforming SME Protection and Digital Healthcare in Malaysia

KUALA LUMPUR, Malaysia, Dec. 9, 2025 /PRNewswire/ -- In a move that reflects the shifting expectations ofMalaysia's modern workforce, VSure Group and virtual healthcare provider HEYDOC Health have jointly launchedCareConnect Suite , a new digital ecosystem aimed at closing long-standing gaps in em...

2025-12-09 15:58 1051

Sweden Recommends: A Dose of Northern Lights Therapy

STOCKHOLM, Dec. 9, 2025 /PRNewswire/ -- As the world's first country to be prescribed for its health benefits,Sweden is now shining a light on one of its most awe-inducing wellness experiences. Aurora Borealis – the original arctic light therapy...

2025-12-09 15:53 774

Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen (oxaliplatin + tegafur/gimeracil/oteracil) as n...

2025-12-09 15:50 865

GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy

YONGIN, South Korea, Dec. 9, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its study analyzing cell-free DNA (cfDNA) fragmentation patterns in 1,154 healthy individuals has been published in Clinical Chemistry (Impact Factor 6.3, 2025). The ...

2025-12-09 14:54 846

Greenyn Biotechnology Launches Insumate® mcIRBP-19 Bitter Melon Peptide, Targeting the Billion-Dollar Health Supplement Market

TAICHUNG, Dec. 9, 2025 /PRNewswire/ -- Backed by New Medical Association Certification, Insumate® Becomes the Only Bitter Melon Peptide Globally Recognized by FDA-NDI, SNQ, and the Taiwan Complementary Medicine Society (TCMS). As global demand for scientifically validated metabolic health ingred...

2025-12-09 10:30 1164

Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia

HONG KONG, Dec. 8, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III HARMONi-6 study (AK112-306) were shared in an oral presentation by ProfessorShun Lu from Shanghai Chest Hospital. The ...

2025-12-09 10:02 1056

Therme Group acquires full Thermengruppe Josef Wund portfolio through Therme Horizon, integrating all four Wund-origin destinations into its global platform

MUNICH, Dec. 9, 2025 /PRNewswire/ -- Therme Group, a leading developer, owner and operator shaping the future of wellbeing infrastructure, today announced the acquisition of three thermal wellbeing destinations — Euskirchen, Sinsheim, and Titisee-Neustadt — from the Josef Wund Foundation. The tra...

2025-12-09 09:00 1092

CGTN: In the wake of tragedy, Hong Kong comes together to rebuild

BEIJING, Dec. 9, 2025 /PRNewswire/ -- CGTN published an article on the post-disaster rescue and reconstruction efforts following a devastating fire in Tai Po in the Hong Kong Special Administrative Region (HKSAR), highlighting the collective efforts by the central government and the HKSAR governme...

2025-12-09 08:54 976

Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...

2025-12-09 08:00 1246

Inheritance + Innovation + Development: The "Co-development" Path of Hakka Medicine and Traditional Chinese Medicine

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- From November 23 to 25, the Seventh World Hakka Entrepreneurs Convention was held in Meizhou,Guangdong. The conference, with the theme of "Gather Global Hakka Entrepreneurs • Facilitate High-Quality Development," upheld the principles of "openness, innovati...

2025-12-09 08:00 989

With Child Deaths Projected to Rise for the First Time in a Century, Gates Foundation and Mohamed Bin Zayed Foundation for Humanity Urge Action as World Faces Critical Turning Point

 At Goalkeepers Abu Dhabi, global leaders outline a path to improve and save the lives of millions of children through lifesaving innovation and renewed investment Partners announce $1.9 billion to advance polio eradication Event held in partnership with the Mohamed bin Zayed Foundation for Huma...

2025-12-09 03:14 1014

EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

PROVIDENCE, R.I., Dec. 9, 2025 /PRNewswire/ -- EpiVax, Inc. , with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publ...

2025-12-09 03:11 1030

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

* In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Menarini Gro...

2025-12-09 03:05 1320
1 ... 78910111213 ... 859

Week's Top Stories